TABLE 1.

Summary of Studies of ¹⁸F-FDG PET for Early Prediction of Treatment Response

					18F-FDG PET metabolic response
Reference	Year	No. of patients included in 18F-FDG PET analysis	Pathologic response criteria*	Percentage of responders	After indicated treatment cycle	Decrease in SUV	Percentage sensitivity	Percentage specificity	Percentage negative predictive value
Schelling et al. (8)	2000	22	pCR + pMRD	29	First, second	> 45% after first or second	100 (first), 83 (second)	85 (first), 94 (second)	N/A
Smith et al. (9)	2000	30	pCR-macro	38	First	>20%	90	74	N/A
Rousseau et al. (10)	2006	64	>50% therapeutic effect	56	First, second	> 40% after first or second	61 (first), 89 (second)	96 (first), 95 (second)	68 (first), 85 (second)
Schwarz-Dose (11)	2009	104	pCR + pMRD	16	First, second	> 45% after first, >55% after second	73	63	90
Humbert et al.† (32)	2012	37	pCR‡	38	First	>75%	64	83	79
Groheux et al.† (35)	2013	30	pCR‡	53	Second	>62%	86	63	N/A
						SUV ≤ 3.0§	86	94	88
Humbert et al.† (34)	2014	54	pCR‡	41	First	>60%	83	52	84
						SUV < 2.1§	59	88	76

^*pCR = pathologic complete response, defined as absence of residual invasive tumor in breast, irrespective of lymph node status [ypT0/is ypNX], unless otherwise indicated; pMRD = minimal residual disease, defined as a few scattered foci of microscopic residual invasive tumor (≤2 mm); pCR-macro = pathologic response, defined as absence of macroscopically visible tumor.

^‡pCR was defined as absence of residual invasive tumor in both breast and axillary lymph nodes [ypT0/is ypN0].

^†Results were based on HER2-positive breast cancers only.

^§Absolute SUVs for defining cutoff values.

N/A = not available.